Abstract
Prognostication of patients with diffuse large B-cell lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (I-PET) in Hodgkin lymphoma, several retrospective and prospective studies are attempting to assess the value of I-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of I-PET scanning in this disease. This is a timely analysis, as tailoring therapies based on prognosis at diagnosis are becoming of increased investigational interest.
Keywords:
Interim imaging; Large-cell lymphoma; Lymphoma; PET scanning; Prognosis.
Copyright © 2016 Elsevier Inc. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B-Lymphocytes / metabolism
-
B-Lymphocytes / pathology
-
Biomarkers, Tumor
-
Biopsy
-
Combined Modality Therapy
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunohistochemistry
-
Immunophenotyping
-
Lymphoma, Large B-Cell, Diffuse / diagnosis*
-
Lymphoma, Large B-Cell, Diffuse / etiology
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Lymphoma, Large B-Cell, Diffuse / therapy
-
Neoplasm Staging
-
Outcome Assessment, Health Care
-
Positron-Emission Tomography / methods*
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Prognosis
-
Rituximab
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Biomarkers, Tumor
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone